Stryker Hip Replacement Implant Recall Lawyers at Wright & Schulte LLC Issue Update on Stryker Rejuvenate and ABG II Recall - KCTV5
Member Center:
This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Wright & Schulte LLC
Wright & Schulte LLC Evaluating Stryker Hip Replacement Recall Lawsuits Stemming from Rejuvenate and ABG II Modular-Neck Hip Stem Recall
Dayton, OH (PRWEB) January 27, 2013
Wright & Schulte LLC, an experienced harmful medical device law firm, is evaluating legal claims stemming from the Stryker hip implant recall for Rejuvenate and ABG II Modular-Neck Hip Stems. Stryker recently updated its recommendations for patients, advising that even those without symptoms of a failing hip implant undergo blood tests for metal ion levels, as well as cross-sectional imaging. According to a Reuters report, the company also reported that the Stryker Rejuvenate and ABG II recall could cost it as much as $390 million. As a result, Stryker has raised its related financial reserves and recorded a fourth-quarter charge of $174 million before taxes.
[stryker.com/en-us/products/Orthopaedics
/modularneckstems/index.htm]
[reuters.com/article/2013/01/09/stryker-recall-
idUSL1E9C95FG20130109]
Wright & Schulte LLC is offering free Stryker Rejuvenate and ABG II lawsuit consultations to individuals who suffered serious complications due to the recalled Stryker Rejuvenate and ABG II Modular-Neck Hip Stems, including:
Stryker recalled the Rejuvenate and ABG components in July 2012. At the time, the company said some 20,000 affected hip stems had been sold globally. Stryker has warned that fretting and corrosion at the modular neck junction could result in pain, swelling, and an adverse local tissue reaction. In its most recent recall update, Stryker said it had received reports of Rejuvenate and ABG II recipients who had high levels of metal ions in their blood, and/or evidence of local tissue reaction, even though they experienced only mild or no symptoms. As such, the company is recommending clinical screening for all Stryker hip implant recall patients.
[http://literature.ortho.stryker.com/files/REJUV_COM_23.pdf
According to Reuters, Stryker said earlier this month that the Rejuvenate and ABG II recall, including expenses for patient testing and treatment, new surgeries, lawsuits and insurance payments, could ultimately cost the company between $190 and $390 million. The final cost will be dependent on a number of factors, including the number of patients who require testing and follow-up procedures and the cost of lawsuits.
A number of Stryker Rejuvenate and ABG II lawsuits have already been filed by individuals allegedly injured by the Rejuvenate and ABG II replacement implants. A petition is currently pending before the New Jersey Supreme Court seeking that all claims filed in the state be centralized in a single proceeding in Bergen County Superior Court. Many of the Stryker Rejuvenate and ABG II lawsuits were filed by plaintiffs who were forced to undergo painful and risky revision surgery to have the Rejuvenate and ABG II stems removed and replaced.
[http://www.judiciary.state.nj.us/notices/2012/n121024f.pdf
About Wright & Schulte LLC
Wright & Schulte LLC, an experienced harmful medical device law firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free case Stryker Rejuvenate and ABG II lawsuit evaluations are available through yourlegalhelp.com, or call 1-888-365-2602.
Contact:
Wright Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-888-365-2602
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10366172.htm
 | 
|
